Manufacturing News of Note—Aurobindo gets 2 483s; Catalent to make BeiGene drug

stocks
(Pixabay)

> The FDA recently posted two Form 483s issued to India’s Aurobindo in October; one for a sterile facility and one for an API facility. 

> CDMO Catalent has been tapped by China's BeiGene, to manufacture its immuno-oncology drug Brukinsa. Release 

> South Korea and Singapore have signed an agreement to work together and share information GMP inspections. Story 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Ingredient supplier Barentz says that private equity firm Cinven has made an investment that will allow it to expand. Story 

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.